Markets are likely to see a negative start owing to muted global cues. The 50-share Nifty is likely to retest the crucial 6,300 levels in today's trade. At 0830 hrs, the SGX Nifty was down 35 points at 6,327.
Asian shares were off-color on Friday, extending the previous day's weakness as disappointing Chinese manufacturing data raised concerns over the economy, and investors sought safety in gold and the yen.
MSCI's broadest index of Asia-Pacific shares outside Japan slipped 0.1 percent, having fallen 1.3 percent in the previous session to a 4-1/2 month low following the Chinese factory activity report.
A decline in the flash Markit/HSBC Purchasing Managers' Index for China, the world's second-largest economy, reinforced concerns about global growth, especially in commodity-sensitive emerging markets.
As the yen strengthened against the dollar, Nikkei futures tumbled 2 percent, pointing to more losses for the Japanese benchmark after dropping 0.8 percent on Thursday.
U.S. stocks fell on Thursday, with the Dow Jones industrial average recording its third consecutive day of losses, as risky assets sold off in wake of disappointing manufacturing data in China.
Financials and materials stocks were the day's biggest losers while telecom services was the only positive sector as investors sold growth-oriented stocks and bought defensive ones. Trading volume was heavier than in recent sessions.
The Dow Jones industrial average fell 1.07 percent, to 16,197, the S&P 500 lost 0.89 percent, to 1,828 and the Nasdaq Composite dropped 0.57 percent, to 4,219.
Stocks to watch
Glenmark, UCO Bank and SKS Microfinance may see some moves ahead of its Q3 numbers expected later in the day.
Cairn India, Bharti Infratel and L&T Finance will be reacting to it Q3 numbers declared yesterday.
Radico Khaitan may see an uptick as Ace investor Rakesh Jhunjhunwala's Rare Enterprises acquired 6.85 lakh shares of the company.
The troubled time continues for Ranbaxy. The stock is likely to see a downhill move after the US Food and Drug Administration banned more products from Indian drug maker Ranbaxy Laboratories Ltd from entering the United States due to manufacturing violations.
